Tatva Chintan Pharma Chem Limited — Q3 FY26 earnings call

Call held 21 Jan 2026

Management summary

Tatva Chintan delivered a strong Q3 FY26, with operating revenue growing 53% YoY to INR1,313 million and EBITDA surging 261% YoY to INR255 million, primarily driven by robust performance in Pharma & Agro Intermediates and Specialty Chemicals, and Structured Directing Agents. The company is actively advancing its capacity expansion, with a new agro intermediate plant nearing commercialization and plans for a greenfield plant at Jolva. Despite some sequential declines in certain segments and ongoing geopolitical uncertainties, management expressed confidence in the chemical industry's stabilization and the company's strategic growth initiatives.

Highlights

  • Operating revenue of INR1,313 million, representing a year-on-year growth of 53% and a sequential growth of 6%.

  • EBITDA for the quarter stood at INR255 million, reflecting a 261% year-on-year growth and a 15% improvement quarter-on-quarter.

  • Pharma & Agro Intermediates and Specialty Chemicals delivered revenue of INR471 million, reflecting a 45% sequential growth and an 86% increase year-on-year.

  • Structured Directing Agents reported revenue of INR534 million, delivering a strong year-on-year growth of 65%.

  • New agro intermediate plant at Dahej has completed engineering and is set for chemical trials from February 1, 2026, with commercial use expected by March 2026.

Concerns

  • Phase Transfer Catalysts reported a 5% decline quarter-on-quarter, with revenue of INR279 million.

  • Structured Directing Agents reported a 10% decline quarter-on-quarter, with revenue of INR534 million.

  • Geopolitical developments and discussions around reciprocal tariffs continue to remain fluid, though management believes they are manageable.

Key financials

  1. Revenue 1,313 Mn +53%YoY
  2. EBITDA 255 Mn +261%YoY

What they filed

Q1 FY27: revenue up 42.7%, net profit up 128.6% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue83 86 108 117 124 +49%131 +52%134 +24%167 +43%
EBITDA6 7 9 17 22 +267%25 +257%28 +211%32 +88%
Net profit-1 0 1 7 10 +1100%15 10 +900%16 +129%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Segment breakdown

Share of Revenue
1,298 Mn Total
  • Structured Directing Agents 534 Mn 41.1%
  • Pharma & Agro Intermediates and Specialty Chemicals 471 Mn 36.3%
  • Phase Transfer Catalysts 279 Mn 21.5%
  • Electrolyte Salts 14 Mn 1.1%

Capital allocation

high confidence
  • Capex Capex disclosed
    • Jolva greenfield plant (Phase 1) ₹250 Cr
    • Dahej new block (recently finished) ₹102 Cr
    • Optimization in terms of achieving better and better margins (for capex over last 1.5 years)
    So this is we will do it in two large phases. So the first phase is going to be greenfield right from filling up land to building compounds, boundary walls and all, common utilities and stuff like that. We expect this phase to have a capex of about INR265 crores, INR270 crores. That final amount we will have within the next week's time. So those final drawings and designing and estimation work is going on. So probably this is where we look at the number between INR250 crores to INR275 crores as capex. And we plan to execute this within 18 months. (Page 8) So current new plant capex was INR102 crores. (Page 10) A lot of recent capacity expansions that we have done is most a lot of it, okay, most I would say 70% of that has not gone towards capacity expansion. Most of this capex has gone towards utilization expansion. So basically, we have observed a lot of bottlenecks in terms of handling the product, moving the product. As I said, certain missing blocks in production, which we are not able to reuse a byproduct. So we are trying to optimize the profit. So this -- the last legs of expenses that have gone actually speaking in last 1.5 years, most of it has gone towards optimization in terms of achieving better and better margins.

Guidance & targets

Revenue

  • Overall Revenue Target Revenue · by 2.5-3 years · Medium confidence INR860 crores to INR900 crores
    2.5 years from now, 3 years let us say on a safer side.

    — Chintan Shah

Revenue Growth

  • FY26 Revenue Growth Revenue Growth · FY26 · High confidence 20% to 30%
    I would definitely say a number between 20% to 30% of growth is definitely achievable.

    — Chintan Shah

  • FY27 Revenue Growth Revenue Growth · FY27 · Medium confidence Similar (20-30%)
    Similar, similar. Because by that time, we'll have a much larger growth potentially if the Jolva plant goes commissioned commercially, right?

    — Chintan Shah

  • Structured Directing Agents (SDA) Growth Revenue Growth · Ongoing · Medium confidence 25% to 30%
    I think, 25% to 30% is what I foresee.

    — Chintan Shah

Margin

  • EBITDA Margin Margin · Ongoing · High confidence 20% to 22%
    I would say somewhere between 20% to 22% is what I always say that this is realistically achievable.

    — Chintan Shah

Revenue Contribution

  • Electrolyte Salts Revenue Contribution Revenue Contribution · Calendar Year 2026 · Medium confidence 7% to 8%
    I believe calendar year '26 will show at least 7% to 8% in terms of revenue coming from this category. So it's quite encouraging the way it is going.

    — Chintan Shah

  • New Agro Product (domestic market) Revenue Revenue Contribution · Calendar Year 2028 · Medium confidence INR150 crores
    We anticipate about INR150 crores from 2028 calendar year, I assume.

    — Chintan Shah

  • New Pharma & Agro Intermediates (6 products) Revenue Revenue Contribution · Calendar Year 2027 · Medium confidence INR200 crores, INR250 crores
    So what I'm saying, potentially, this will hit somewhere about INR200 crores, INR250 crores in revenue in calendar year 2027.

    — Chintan Shah

Commercialization Timeline

  • Semiconductor Chemicals Full-Scale Commercialization Commercialization Timeline · 2028 · Medium confidence around 2028
    Absolutely. But it's going to be somewhere around 2028 when it goes to full-scale commercialization.

    — Chintan Shah

  • Pharma Commercialization (new products) Commercialization Timeline · Q2 FY27 · Medium confidence second quarter of next financial year
    On the pharmaceutical side, we expect commercialization to consolidate from the second quarter of next financial year.

    — Ajesh Pillai

  • Agro Intermediate (new product from Jolva) Commercialization Commercialization Timeline · within 18 months · Medium confidence over the next 18 months
    As the project advances towards commercialization over the next 18 months, it will significantly enhance our operational flexibility and scalability.

    — Chintan Shah

  • Jolva Plant Commissioning Commercialization Timeline · Sep-Oct 2027 · High confidence September or October of 2027
    So the time line for Jolva plant to get commissioned and put to use, potentially, we are looking at September or October of 2027.

    — Chintan Shah

What to watch in Q4 FY26

Agrochemical New Plant Commercialization

Next quarter (Q4 FY26)
Current Engineering complete, water trials ongoing
Target Chemical trials commenced, validation trials started, commercial use by March 2026

Why it matters

This plant is key for new agro intermediate products and addressing current production bottlenecks, impacting future revenue and efficiency.

So today, the engineering team has handed over the plant to the production team. So now they are doing the first set of water trials, and we expect to have trials -- chemical trials beginning from 1st of February and potentially begin validation trials from 16th of February.

Risks & concerns

  • Geopolitical Developments & Reciprocal Tariffs

    medium

    Geopolitical developments and discussions around reciprocal tariffs, particularly in the United States, continue to remain fluid.

    Management acknowledged

  • Agrochemical Industry Pricing Pressure

    medium

    The agrochemical industry is still undergoing pricing pressure and recovery is uncertain, but Tatva's innovative technologies offer differentiation.

    Analyst differentiated

  • SDA Demand Cyclicality/Lumpiness

    medium

    SDA business is campaign-based, leading to fluctuating demand and making quarter-on-quarter analysis difficult.

    Analyst acknowledged

  • Semiconductor Chemicals Gradual Commercialization

    low

    The path to full commercialization for semiconductor chemicals will be gradual, despite long-term significance.

    Management acknowledged

Q&A highlights

8 direct
Agrochemical New Plant Commercialization Timeline Direct
So today, the engineering team has handed over the plant to the production team. So now they are doing the first set of water trials, and we expect to have trials -- chemical trials beginning from 1st of February and potentially begin validation trials from 16th of February.

Provides specific, near-term milestones for a key new capacity addition in the agrochemical segment.

Asked by Sanjesh Jain

Agrochemical Market Outlook and Tatva's Strategy Direct
The thing, which probably differentiates my views from the rest of the industry is because we had absolutely nearly no presence in this sector, let us say, a year or two years back. So whatever development that we have brought into this segment has come with lot of innovative technologies.

Explains management's confidence in the agrochem segment despite broader industry pricing pressures, attributing it to innovative technology and new market entry.

Asked by Sanjesh Jain

Jolva Greenfield Project Capex and Timeline Direct
So this is we will do it in two large phases. So the first phase is going to be greenfield... We expect this phase to have a capex of about INR265 crores, INR270 crores... And we plan to execute this within 18 months.

Quantifies the initial investment and timeline for a significant new greenfield expansion, indicating future growth drivers.

Asked by Sanjesh Jain

Semiconductor Chemicals Plant Trial Order Direct
So this is just a small trial order, a few thousand dollars. Just a small plant trial order and test whether we can scale up the products from pilot to the plant in the same way with this desired quality. So this is kind of a testing purpose.

Clarifies the early, validation-focused stage of the first semiconductor plant trial order, managing expectations for immediate revenue impact.

Asked by Sanjesh Jain

SDA Segment Sequential Decline Direct
Don't track SDA on a sequential basis, I would request please track SDAs on an annual basis because of the way the business is happening is in kind of what you call the campaign basis.

Provides crucial context for interpreting SDA segment performance, explaining its inherent lumpiness and why sequential analysis is less relevant.

Asked by Raman KV

Dahej New Block Capex and Overall Revenue Potential Direct
So current new plant capex was INR102 crores... Now what we foresee is this plant as a whole... I would say now we can achieve at the current pricing levels, we feel confident to reach up to a level of INR850 crores to INR900 crores in terms of overall revenue.

Details the investment in the Dahej new block and its contribution to the company's overall revenue potential, emphasizing its role in operational efficiency and cost leverage.

Asked by Raman KV

Semiconductor Opportunity Size Direct
But these are very large volume products. And so what see, this is all, let us say, if I'm saying it's a INR100 crores opportunity, for example, to give a number. But in reality, it could be a INR2,000 crores opportunity.

Highlights the significant long-term potential of the semiconductor chemicals segment, even though it is currently in early development stages.

Asked by Nirali Gopani

SDA Capacity Utilization Direct
It's now roughly about 50% today, it had gone down 35, now it's roughly about 55. So we have enough capacities to go on without any further capex as of now at this stage.

Provides current capacity utilization for a key segment and indicates headroom for growth without immediate capex requirements.

Asked by Mohit Jain

2 min read 6 chapters

Detailed narrative

Strong Q3 FY26 Performance Driven by Specialty Segments

Tatva Chintan reported a robust Q3 FY26, with operating revenue reaching INR1,313 million, marking a 53% year-on-year and 6% sequential growth. EBITDA for the quarter stood at INR255 million, reflecting a significant 261% year-on-year and 15% quarter-on-quarter improvement. This strong performance was primarily fueled by Pharma & Agro Intermediates and Specialty Chemicals, which grew 86% YoY to INR471 million, and Structured Directing Agents, up 65% YoY to INR534 million.

New Capacity & Commercialization Progress

The company is on track with its capacity expansion plans. The engineering for the new agro intermediate plant at Dahej is complete, with water trials underway and chemical trials scheduled to begin on February 1, 2026, leading to commercial use by March 2026. This INR102 crore investment is aimed at debottlenecking and improving operational efficiency. Additionally, preparatory work for the new greenfield plant at Jolva, with an initial capex of INR250-275 crores, is progressing for a groundbreaking in the current quarter, targeting commercialization within 18 months.

Strategic Focus on High-Growth Segments

Tatva Chintan is strategically focusing on high-growth and specialty segments. Electrolyte Salts, a distinct strategic focus, achieved INR14 million in revenue, growing 14% both sequentially and YoY, and is projected to contribute 7-8% of total revenue by calendar year 2026, up from current 1%. The Semiconductor Chemicals segment is also making steady progress, with the first plant trial order for a few thousand dollars expected in early February, though full-scale commercialization is anticipated around 2028.

Differentiated Approach in Agrochemicals

Despite general industry pricing pressure in agrochemicals, Tatva Chintan maintains a positive outlook due to its innovative technologies, particularly catalytic and electrolytic chemistries. Having had minimal presence in this sector previously, the company's new product developments offer a 'winning situation' for customers while sustaining margins. This approach is expected to drive significant growth, with new agro products projected to contribute INR150 crores by 2028 and a total of INR200-250 crores from six new pharma and agro intermediates by calendar year 2027.

Long-Term Revenue and Margin Outlook

Management provided a long-term revenue target of INR860-900 crores within 2.5 to 3 years, driven by new capacities and product commercialization. For FY26, revenue growth is expected to be between 20-30%, with similar growth anticipated for FY27, especially with the Jolva plant commissioning by September-October 2027. EBITDA margins are expected to stabilize between 20-22%, reflecting the benefits of operational optimization and new technology.

Market Environment and SDA Dynamics

The chemical industry is showing signs of stabilization and recovery, with improved visibility of growth across end-use segments. Customer order patterns are becoming more predictable. For Structured Directing Agents (SDA), management advises tracking performance annually rather than sequentially due to its campaign-based nature, which can lead to quarterly fluctuations. Current SDA capacity utilization is around 50-55%, providing ample headroom for the projected 25-30% growth without immediate further capex.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Chemicals earnings calls